MRNA Free cash flow
Free cash flow at Moderna rose to −$2.1B in fiscal 2025, from −$4.1B in 2024.
Not a GAAP measure. Derived here as operating cash flow less capital expenditure, both as filed; the arithmetic is shown in the table.
SOURCE: us-gaap:NetCashProvidedByUsedInOperatingActivities + us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · EDGAR CompanyFacts · CIK 1682852 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|
| FY2025 | −$1.9B | −$192M | −$2.1B |
| FY2024 | −$3.0B | −$1.1B | −$4.1B |
| FY2023 | −$3.1B | −$707M | −$3.8B |
| FY2022 | $5.0B | −$400M | $4.6B |
| FY2021 | $13.6B | −$284M | $13.3B |
More SAME DATA, OTHER VIEWS
Free cash flow across coverage → · MRNA company view →
Revenue · Net income · Operating cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.